Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Algeta ASA
Woman Max 99 years
Algeta ASA
Update Il y a 4 ans
An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy
To investigate if multiple intravenous injections of Alpharadin have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocri...
Country
None
organs
None
Specialty
None
unknown
More information
Man
Between 18 years
and 99 years
Algeta ASA
Update Il y a 4 ans
Algeta ALSYMPCA : Essai de phase 3 randomisé évaluant l'efficacité et la tolérance de l'alpharadin, chez des patients ayant un cancer de la prostate. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A double-blind, randomised, multiple dose, phase III, multicentre study of alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
Country
France
organs
Prostate
,
Os
,
Métastases osseuses
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Man Max 99 years
Algeta ASA
Update Il y a 4 ans
A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases
To compare the proportion of patients with PSA response (PSA decrease of 50% from baseline, confirmed three weeks later) of three different repeat dose regimens of Alpharadin in patients with hormone ...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Algeta ASA, Oslo, Norway
Update Il y a 4 ans
A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients
The primary objective of this study is to investigate whether there is a dose-response relationship for radium-223 in patients with painful bone metastases secondary to prostate carcinoma regarding th...
Country
None
organs
None
Specialty
None
unknown
More information